TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas

Journal of Pathology

Volumn 181, Issue 2, 1997, Pages 158-165

  Skomedal, Hanne ^a   Kristensen, Gunnar B ^a   Abeler, Vera M ^a   Børresen Dale, Anne Lise ^a   Tropé, Claes ^a   Holm, Ruth ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Immunohistochemistry; MDM2; Ovarian borderline tumours; Ovarian stage I carcinomas; p53 mutation; TP53; Tumour suppressor genes

Indexed keywords

PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; CLEAR CELL CARCINOMA; EARLY CANCER; ENDOMETRIUM CARCINOMA; FEMALE; GEL ELECTROPHORESIS; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FEMALE; GENE EXPRESSION; GENES, P53; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031018178     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199702)181:2<158::AID-PATH742>3.0.CO;2-8     Document Type: Article

References (39)

1. Levine AJ, Perry ME, Chang A. The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 1994; 69: 409-416.
2. Hollstein M, Rice K, Greenblatt MS, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994; 22: 3551-3555.
3. Levine AJ, Momand J, Finlay, CA. The TP53 tumour suppressor gene. Nature 1991; 351: 453-456.
4. Lane DP. The regulation of TP53 function: Steiner award lecture. Int J Cancer 1994; 57: 623-627.
5. Fritche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor suppressor protein by DNA-damaging agents. Oncogene 1993; 8: 307-318.
6. Lane DP, Crawford LV. T antigen is bound to a host protein in SV 40-transformed cells. Nature 1979; 278: 261-263.
7. Momand J, Zambetti GP, Olson DC, Levine AJ. The mdm-2 oncogene product forms a complex with the TP53 protein and inhibits TP53-mediated transactivation. Cell 1992; 69: 1237-1245.
8. Oliner KD, Kinzler KW, Metzler PS, George D, Vogelstein B. Amplification of a gene encoding a p53 associated protein in human sarcomas. Nature 1992; 358: 80-83.
9. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas, without p53 mutations. Cancer Res 1993; 53: 2736-2739.
10. Chang J, Bridgewater J, Gore M, et al. Non-surgical aspects of ovarian cancer. Lancet 1994; 343: 335-341.
11. Makar APH, Kristensen GB, Kærn J, Børmer OP, Abeler VM, Tropé CG. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol 1992; 79: 1002-1010.
12. Abder V, Kjørstad KE, Nesland JM. Small cell carcinoma of the ovary. A report of six cases. Int J Gynecol Pathol 1988; 7: 315-329.
13. Milner BJ, Allan LA, Eccles DM, et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993; 53: 2128-2132.
14. Mazars R, Pujol R, Maudelonde T, Jeanteur P, Theiller C. p53 mutations in ovarian cancer: a late event. Oncogene 1991; 6: 1685-1690.
15. Kohler MF, Kerns B-JM, Humphrey PA, et al. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 1993; 81: 643-650.
16. Kupryjanczyk J, Bell DA, Dimeo D, Beauchamp R, Thor AD, Yandell DW. p53 gene analysis of ovarian borderline tumors and stage 1 carcinomas. Hum Pathol 1995; 26: 387-392.
17. Foulkes WD, Stamp GWH, Afzal S, et al. MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. Br J Cancer 1995; 72: 883-888.
18. Hsu S-M, Raine L, Fanger H. A comparative study of the peroxidase-antiperoxidase method and tin avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol 1981; 75: 734-738.
19. Cattoreti G, Becker HG, Key G, et al. Monoclonal antibodies against recombinant parts of Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992; 168: 357-363.
20. Mies C, Huldsworth J, Chaganti RSK. Extraction of DNA frorn paraffin blocks for Southern blot analyses. Am J Surgs Pathol 1991; 15: 169-174.
21. Andersen TI, Børresen A-L. Alterations of the TP53 gene as a potential marker in breast carcinomas: advances of using constant denaturing gel electrophoresis in mutation detection. Diagn Mol Pathol 1995; 4: 203-211.
22. Hovig E. Smith-Sørensen B, Brogger A, Børresen A-L. Constant denaturant gel electrophoresis, a modification of denaturing gradient gel electrophoresis in mutation detection. Mutat Res 1991; 262: 63-71.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
24. Tarone RE, Ware J. On distribution-free tests for equality and survival distributions. Biometrika 1977; 64: 156-160.
25. Cox DR. Regression models and life-tables. J R Stat Soc B 1972; 34: 187-220.
26. Berchuck A, Kohler MF, Marks JR, et al. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 1994; 170: 246-252.
27. Holm R, Nesland JM. Retinoblastoma and p53 tumour suppressor gene protein expression in carcinomas of the thyroid gland. J Pathol 1994; 172: 267-272.
28. Karlsen F, Kalantari M, Chitemerere M, Johansson B, Hagmar B. Modifications of human and viral deoxyribonucleic acid by formaldehyde fixation. Lab Invest 1994; 71: 604-610.
29. Carbone D, Chiba I, Mitsudomi T. Polymorphism at codon 213 within the p53 gene. Oncogene 1991; 6: 1691-1692.
30. Condie A, Eeles R, Børresen A-L, Coles C, Cooper C, Prosser J. Detection of point mutations in the TP53 gene: comparison of single-strand conformation polymorphism, constant denaturant gel electrophoresis and osmium tetroxide techniques. Hum Mutat 1993; 2: 58-66.
31. Skomedal H, Kristensen GB, Heiland À, et al. TP53 gene mutations and protein accumulation in primary vaginal carcinomas. Br J Cancer 1995; 72: 129-133.
32. Helland Å, Holm R, Kristensen G, et al. Genetic alterations of the TP53 gene, TP53 protein expression and HPV infection in primary cervical carcinomas. J Pathol 1993; 171: 105-114.
33. Hall PA, McKee PH, Menage H du P, Dover R, Lane DP. High levels of TP53 protein in UV-irradiated normal human skin. Oncogene 1993; 8: 203-207.
34. Leach FS, Tokino T, Meltzer P, et al. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993; 53: 2231-2234.
35. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994; 54: 794-799.
36. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. FMBO J 1993; 12: 461-468.
37. Landers JE, Haines DS, Strauss JF, George DL. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cell. Oncogene 1994; 9: 2745-2750.
38. Bosari S, Viale G, Radaelli U, Bossi P, Bunoldi E, Coggi G. p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol 1993; 24: 1175-1179.
39. Lavesque MA, Kalsaros D, Yu H, et al. Mutant p53 overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995; 75: 1327-1338.